Ultragenyx Pharmaceutical
Advancing medicines for rare disease
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥1,001-5,000
📍Novato, CA
Ultragenyx Pharmaceutical

About Ultragenyx Pharmaceutical

About Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

What Ultragenyx Pharmaceutical is building

Ultragenyx Pharmaceutical product / service
Ultragenyx Pharmaceutical product / service
Ultragenyx Pharmaceutical product / service
Ultragenyx Pharmaceutical product / service
Ultragenyx Pharmaceutical product / service
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.

Technologies used at Ultragenyx Pharmaceutical

Front-end (1)
Back-end (4)
AzureAzure

Company culture

Ultra-Impact

Those in the rare disease community are our heroes. See how we’re empowered to put them first.

Ultra-Focused

We are creative collaborators motivated by the real-world impact of our treatments.

See more

Funding rounds

Total Funding

Total Funding

$185M
Last funding round type

Last funding round type

Post-IPO Equity
Company type

Company type

For Profit

Ultragenyx Pharmaceutical news and updates

Dier left Ultragenyx Pharmaceutical Inc. as Executive Vice President and CFO on Oct 10th 22'.

Dier joined Acelyrin from Ultragenyx Inc., where she most recently served as executive vice president and chief financial officer.

Nov 10, 2022 | sfvbj.com

Mardi Dier left Ultragenyx Pharmaceutical Inc. as chief financial officer and executive vice president on Nov 15th 22'.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC.

Nov 9, 2022 | ultragenyx.com

Ultragenyx Pharmaceutical Inc. hired Amrit Ray on Apr 22nd 22'.

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors Amrit Ray, M.D., M.B.A. NOVATO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors.

Jan 1, 2022 | ultragenyx.com

Regeneron Pharmaceuticals Inc. partners with Ultragenyx Pharmaceutical Inc.

Regeneron is taking care of development and distribution in the U.S. and is collaborating with Ultragenyx for activities outside the country.

Jan 1, 2022 | biospace.com

Regeneron partners with Ultragenyx Pharmaceutical Inc.

Regeneron is responsible for developing and distributing Evkeeza in the U.S. and is collaborating with Ultragenyx ( RARE ) to develop and sell Evkeeza outside the U.S.

Jan 1, 2022 | seekingalpha.com

Ultragenyx Pharmaceutical Inc. launches Crysvita

“Ultragenyx has successfully launched Crysvita, meaningfully improving the lives of thousands of pediatric and adult patients with two rare diseases.

Jan 1, 2022 | omerscapitalmarkets.com

Ultragenyx Pharmaceutical Inc. is developing GeneTx’s GTX-102 on Jan 9th 20'.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.

Jan 1, 2020 | genetxbio.com

Ultragenyx Pharmaceutical Inc. is developing GTX-102 with Ultragenyx on Aug 1st 19'.

In August 2019, Ultragenyx and GeneTx announced a partnership to develop GTX-102 with Ultragenyx receiving an exclusive option to acquire GeneTx.

Jan 1, 2020 | genetxbio.com

Ultragenyx Pharmaceutical Inc. is developing GTX-102 on Aug 1st 19'.

In August 2019, GeneTx and Ultragenyx announced a partnership to develop GTX-102, with Ultragenyx receiving an exclusive option to acquire GeneTx.

Jan 1, 2020 | genetxbio.com

Ultragenyx Pharmaceutical Inc. partners with Kyowa Kirin

Ultragenyx Pharmaceutical Inc. and partner Kyowa Hakko Kirin Co. Ltd. (KHK) have won FDA approval for Crysvita (burosumab), making it the first U.S.-approved treatment for X-linked hypophosphatemia (XLH), a rare, inherited form of rickets.

Jan 1, 2018 | bioworld.com
See More